Clin2
NCT07619118Possibly a fitNot yet recruiting

New cholesterol-lowering combination pill for heart disease prevention

Hypercholesterolaemia

Part of Hormones & metabolism clinical trials.

This study tests a new combination pill (laroprovstat plus rosuvastatin) versus rosuvastatin alone to lower LDL cholesterol (the 'bad' cholesterol that builds up in arteries). If you have a history of heart disease or stroke, or are at high risk for one, this trial may help you reduce that risk further.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
200 people
Ages
18 years to 130 years
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You are currently on a stable dose of cholesterol-lowering medication that works well for you
  • You take the highest dose of statin (cholesterol drug) that your body can safely handle
  • You have a history of heart attack, stroke, or heart disease, OR you are at high risk for developing heart disease
  • Your blood pressure is controlled (not severely high)
  • Your diabetes (if you have type 2) is well-managed, and your thyroid is treated properly

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07619131Not yet recruiting· Phase 3
New cholesterol-lowering combination pill for at-risk adults

This study tests a new combination pill containing two cholesterol-lowering medications (laroprovstat and rosuvastatin) in people who have never taken cholesterol medicine before. The goal is to see if the combination works better than either medicine alone at lowering LDL cholesterol, which is the 'bad' cholesterol that can increase heart disease risk.

NCT07474649Not yet recruiting· Phase 3
Study of a cholesterol-lowering combination pill for patients without heart events

This trial tests a triple therapy pill (bempedoic acid, ezetimibe, and a high-intensity statin) in patients who have extensive plaque in their heart arteries but have never had a heart attack or stroke. It aims to see if this combination can further lower cholesterol and prevent future problems.

Berlin
NCT06186037Recruiting· Phase 4
Lower-dose combo vs. higher-dose alone for heart artery disease

This trial compares a lower-dose cholesterol pill (rosuvastatin plus ezetimibe) to a higher-dose version of just rosuvastatin for people with mild to moderate heart artery blockages who have not had a stent or bypass. It aims to see which approach works better and is safer.

Suwon, Gyeonggi-do
NCT07083206Recruiting
Pitavastatin/ezetimibe for high cholesterol

This trial tests a combination pill of two cholesterol-lowering medicines (pitavastatin and ezetimibe) in adults who have been taking either atorvastatin or rosuvastatin for at least 3 months. It aims to see if switching to this new combination is safe and effective.

Yongin-si
NCT06314919Recruiting
Study of a combination pill for high cholesterol

This study tests a single pill that combines two cholesterol-lowering medicines (pitavastatin and ezetimibe). It may be a good fit if you already take a statin or a statin plus ezetimibe and your doctor wants to adjust your treatment.

Seoul
NCT07441317Not yet recruiting· Phase 3
Testing a new drug for stubborn high cholesterol

This trial tests a new medication (QLC7401) for people with high cholesterol that is not well controlled by their current treatment. It aims to see if the drug can help lower LDL-C (bad cholesterol) levels and reduce the risk of heart problems.

Hear when a new Hypercholesterolaemia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.